Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Switching to Preservative-Free Latanoprost-Timolol in Glaucoma or Ocular Hypertension Patients With Ocular Surface Disease
NCT04891588Unknown
- Sponsor
- Clinical Hospital Center Zagreb
- Start
- Mar 2021
- Primary completion
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of latanoprost ophthalmic solution 0.005% (TearClear TC-002) and timolol in primary open-angle glaucoma (POAG) and ocular hypertension, sponsored by Clinical Hospital Center Zagreb. Primary endpoints: Change of drug tolerability at 6 months, Change of symptoms of ocular surface disease at 6 months and 3 more. Status: unknown.
02
Drugs
latanoprost ophthalmic solution 0.005% (TearClear TC-002)timolol
03
Conditions
primary open-angle glaucoma (POAG)ocular hypertension
Beyond the preview
Go deeper on NCT04891588.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04891588.